In this week’s edition, a Labcorp blood test identifies signs of neurodegenerative disease; the FDA approves an oral treatment for partial seizures in teens; ketamine shows efficacy in epilepsy; and more.

Read the full coverage here:

Labcorp blood test identifies signs of neurodegenerative disease

FDA approves oral treatment for partial seizures in patients aged 16 years and older

Ketamine effective treatment for neonatal, pediatric epilepsy

FDA places hold on phase 2/3 clinical trial of stroke therapy

Hypertension, obesity, physical inactivity among highest risk factors for dementia

References:

Jacobwitz M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200889.

Lee M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.19672.

Press Release

Press Release

Press Release